Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT03776812 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

178

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent Ovarian Cancer
Recurrent Fallopian Tube Carcinoma
Recurrent Primary Peritoneal Carcinoma

Interventions

DRUG: Relacorilant
DRUG: Nab-paclitaxel

Sponsor

Corcept Therapeutics